JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266056

Human CEP57 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

CEP57 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 50 bp deletion in exon 1 and Insertion of the selection cassette in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human CEP57 knockout HeLa cell line (AB266056)
  • Sanger seq

Unknown

Sanger Sequencing - Human CEP57 knockout HeLa cell line (AB266056)

Allele-2 : Insertion of the selection cassette in exon 1.

Sanger Sequencing - Human CEP57 knockout HeLa cell line (AB266056)
  • Sanger seq

Unknown

Sanger Sequencing - Human CEP57 knockout HeLa cell line (AB266056)

Allele-3 : Insertion of the selection cassette in exon 1.

Sanger Sequencing - Human CEP57 knockout HeLa cell line (AB266056)
  • Sanger seq

Unknown

Sanger Sequencing - Human CEP57 knockout HeLa cell line (AB266056)

Allele-1 : 50 bp deletion in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 50 bp deletion in exon 1 and Insertion of the selection cassette in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266056-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266056-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266056 Human CEP57 knockout HeLa cell line", "number":"AB266056-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266056-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266056-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266056 Human CEP57 knockout HeLa cell line", "number":"AB266056-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266056-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266056 Human CEP57 knockout HeLa cell line", "number":"AB266056-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266056-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266056 Human CEP57 knockout HeLa cell line", "number":"AB266056-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
CEP57
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CEP57 also known as Centrosomal Protein 57 or Translokin is a protein with a molecular mass of approximately 57 kDa. CEP57 plays an important mechanical role in the centrosome which is important for the organization of microtubules during cell division. This protein localizes in the centrosome area within the cell cytoplasm. Expression of CEP57 is widespread occurring in various tissues which suggests its function is significant in different cellular contexts.
Biological function summary

CEP57 is important for proper cell division and spindle pole formation. It interacts within a complex of centrosomal proteins playing roles in microtubule nucleation and stabilization. CEP57 also functions as a microtubule-binding protein aiding the accurate segregation of chromosomes during mitosis. By stabilizing microtubule-kinetochore attachments CEP57 ensures effective chromosomal distribution hence maintaining genomic integrity and preventing potential cellular abnormalities.

Pathways

CEP57 contributes significantly to the cell cycle and mitotic spindle organization pathways. It works alongside other centrosomal proteins such as CEP192 and γ-tubulin enhancing their interaction and stabilization of microtubules. CEP57 is also linked to the microtubule-organizing center integrating into pathways important for cell division and duplication processes which are central to maintaining cellular homeostasis and function.

Researchers have associated CEP57 with certain cancers and mosaic variegated aneuploidy syndrome. In cancer overexpression or altered function of CEP57 might lead to improper cell division contributing to tumorigenesis. Furthermore in mosaic variegated aneuploidy syndrome improper function of CEP57 leads to chromosomal instability and abnormal cell growth. CEP57 involvement in these diseases highlights its interactions with other proteins such as TP53 which also manages cell cycle regulation and genomic stability.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com